Price T Rowe Associates Inc Neoleukin Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $2,883 - $7,051	-3,134 Reduced 13.37%	20,300 $21,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $12,728 - $38,702	7,400 Added 46.15%	23,434 $44,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $465 - $775	-100 Reduced 0.62%	16,034 $77,000
Q3 2021 Nov 15, 2021	SELL	$6.05 - $9.66 $117,370 - $187,404	-19,400 Reduced 54.6%	16,134 $117,000
Q2 2021 Aug 16, 2021	BUY	$9.23 - $13.12 $45,596 - $64,812	4,940 Added 16.15%	35,534 $328,000
Q1 2021 May 17, 2021	BUY	$11.26 - $15.78 $118,432 - $165,974	10,518 Added 52.39%	30,594 $377,000
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $204,172 - $292,306	20,076 New	20,076 $283,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.